ViewPoints Interview: Biogen’s Monica Mann Shares Insight on Plegridy to Treat Multiple Sclerosis
Shots: The update in the development is based on ASPIRO P-I/II study results assessing AT132 in 12 patients aged≤ 5 yrs. following a pre-IND meeting of AT132 with FDA in Dec, 2018 for XLMTM, occurred due to mutations in the MTM1 gene The FDA meeting is in response to review nonclinical, clinical, chemistry, manufacturing and controls […]Read More
